Inovio expands manufacturing for COVID-19 vaccine

By The Science Advisory Board staff writers

May 1, 2020 -- Inovio has partnered with German contract manufacturer Richter-Helm BioLogics to produce large-scale quantities of Inovio's investigational DNA vaccine.

The INO-4800 vaccine is currently being tested in the U.S. through a phase I clinical trial. If proved safe, it could advance to phase II and III clinical trials later this year. Meanwhile, Richter-Helm BioLogics will transfer and rapidly scale up production processes for the INO-4800 DNA plasmid using its VGXI manufacturing technology.

The manufacturing partnership, which aims to produce 1 million doses of INO-4800 in 2020, is partly funded through a $1.3 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI). Inovio also partners with Richter-Helm BioLogics for its DNA medicine candidate VGX-3100 for the potential treatment of HPV-related precancerous cervical dysplasia.

COVID-19: A double-edged sword for the pharma industry
The COVID-19 pandemic is causing major disruptions to pharmaceutical R&D activities, despite the pressing need for treatments and diagnostics for the...
CEPI, Clover to partner on COVID-19 vaccine
The Coalition for Epidemic Preparedness Innovations (CEPI) and Clover Biopharmaceuticals Australia plan to partner on the development of a COVID-19 vaccine.
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...
DOD grant accelerates SARS-CoV-2 vaccine manufacturing
The U.S. Department of Defense (DOD) has awarded Ology Bioservices and Inovio Pharmaceuticals an $11.9 million contract to rapidly manufacture DNA...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter